This announcement is a separate document:
百诚医药：国金证券股份有限公司关于杭州百诚医药科技股份有限公司2024年半年度持续督导跟踪报告
Hangzhou Bio-Sincerity Pharma-Tech: Sinolink Securities Co., Ltd.'s Continuous Supervision and Follow-up Report on Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.'s 2024 Half-Yearly
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated